Effect of colesevelam on lovastatin pharmacokinetics

被引:21
作者
Donovan, JM
Kisicki, JC
Stiles, MR
Tracewell, WG
Burke, SK
机构
[1] GelTex Pharmaceut, Clin Res, Waltham, MA 02451 USA
[2] MDS Harris, Lincoln, NE USA
关键词
colesevelam; combination therapy; lovastatin;
D O I
10.1345/aph.1A144
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: To assess potential interactions of colesevelam hydrochloride and lovastatin in healthy volunteers when lovastatin alone was administered with dinner, both lovastatin and colesevelam were administered with dinner, and colesevelam was administered with dinner and lovastatin was administered 4 hours later with a snack. METHODS: A single-center, open-label, 3-period, crossover drug interaction study was performed with 22 healthy volunteers. Blood samples were collected at specified intervals before and after dosing, and plasma concentrations of lovastatin and lovastatin hydroxyacid were measured using a liquid chromatography/mass spectroscopy/mass spectroscopy method. RESULTS: Maximal concentration (C-max), AUC from time 0 to the last time point measured (AUC(0-t)), and AUC(0-infinity), values for lovastatin were 102%, 94%, and 104%, and for lovastatin hydroxyacid were 102%, 91%, and 92%, respectively, of control values when colesevelam and lovastatin were coadministered with dinner. Administration of colesevelam with dinner and lovastatin 4 hours later with a snack resulted in a decreased C-max and AUC(0-t) for lovastatin (63% and 37%, respectively; p < 0.05) and an increased C-max and AUC(0-t) for lovastatin hydroxyacid (61% and 50%, respectively; p < 0.05), both compared with lovastatin alone administered with dinner. CONCLUSIONS: Colesevelam had no significant effect on lovastatin pharmacokinetics when coadministered with lovastatin at dinner. A split-dosing regimen resulted in alterations in pharmacokinetic parameters for lovastatin and lovastatin hydroxyacid that are likely due to known differences in the pharmacokinetics of lovastatin when administered to patients with meals or in a fasting state.
引用
收藏
页码:392 / 397
页数:6
相关论文
共 43 条
  • [1] [Anonymous], 2000, POLYM PREPRINTS
  • [2] Bailey DG, 2000, CLIN PHARMACOL THER, V67, P690
  • [3] A RANDOMIZED PILOT TRIAL OF LOW-DOSE COMBINATION LIPID-LOWERING THERAPY FOLLOWING CORONARY-ARTERY BYPASS-GRAFTING
    BARBIR, M
    HUNT, BJ
    GALLOWAY, D
    TAYLOR, A
    ILSLEY, C
    MITCHELL, A
    YACOUB, M
    [J]. CLINICAL CARDIOLOGY, 1994, 17 (02) : 59 - 64
  • [4] Drug interactions of lipid-altering drugs
    Bays, HE
    Dujovne, CA
    [J]. DRUG SAFETY, 1998, 19 (05) : 355 - 371
  • [5] REGRESSION OF CORONARY-ARTERY DISEASE AS A RESULT OF INTENSIVE LIPID-LOWERING THERAPY IN MEN WITH HIGH-LEVELS OF APOLIPOPROTEIN-B
    BROWN, G
    ALBERS, JJ
    FISHER, LD
    SCHAEFER, SM
    LIN, JT
    KAPLAN, C
    ZHAO, XQ
    BISSON, BD
    FITZPATRICK, VF
    DODGE, HT
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1990, 323 (19) : 1289 - 1298
  • [6] A RECEPTOR-MEDIATED PATHWAY FOR CHOLESTEROL HOMEOSTASIS
    BROWN, MS
    GOLDSTEIN, JL
    [J]. SCIENCE, 1986, 232 (4746) : 34 - 47
  • [7] Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
    Cleeman, JI
    Grundy, SM
    Becker, D
    Clark, LT
    Cooper, RS
    Denke, MA
    Howard, WJ
    Hunninghake, DB
    Illingworth, DR
    Luepker, RV
    McBride, P
    McKenney, JM
    Pasternak, RC
    Stone, NJ
    Van Horn, L
    Brewer, HB
    Ernst, ND
    Gordon, D
    Levy, D
    Rifkind, B
    Rossouw, JE
    Savage, P
    Haffner, SM
    Orloff, DG
    Proschan, MA
    Schwartz, JS
    Sempos, CT
    Shero, ST
    Murray, EZ
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19): : 2486 - 2497
  • [8] Role of the enterohepatic circulation of bile salts in lipoprotein metabolism
    Cooper, AD
    [J]. GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 1999, 28 (01) : 211 - +
  • [9] Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia
    Davidson, MH
    Toth, P
    Weiss, S
    McKenney, J
    Hunninghake, D
    Isaacsohn, J
    Donovan, JM
    Burke, SK
    [J]. CLINICAL CARDIOLOGY, 2001, 24 (06) : 467 - 474
  • [10] Colesevelam hydrochloride (Cholestagel) - A new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects
    Davidson, MH
    Dillon, MA
    Gordon, B
    Jones, P
    Samuels, J
    Weiss, S
    Isaacsohn, J
    Toth, P
    Burke, SK
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1999, 159 (16) : 1893 - 1900